Background
==========

The HVTN 503/Phambili study, a phase IIB study of the Merck Ad-5 multiclade HIV vaccine, suspended enrollment and vaccinations following the results of the HVTN502/STEP study. Participants were notified of their treatment allocation and continue to be followed. We investigate the impact of study unblinding on HIV risk perception and behaviour.

Methods
=======

Before suspension, 801 participants were enrolled. Data from all participants who had a post-treatment notification behaviour risk assessment (PTN-RA) were compared with the baseline RA. In addition an unblinding risk perception questionnaire was administered post-treatment notification (PTN).

Results
=======

469 participants were eligible for risk behaviour analysis: median time between unblinding and administration of PTN-RA being 70 days (IQR: 39--108 days). At baseline, amongst men, there were no statistical differences in risk behaviour reported by treatment arm, and borderline differences in unprotected anal sex with a female partner (0% vaccinee vs. 2.9% placebo arm, p = 0.056), and a STI diagnosis (7.7% vaccinee vs. 2.2% placebo, p = 0.052). For women, there were no differences in risk behaviour by treatment arm at baseline. Post-treatment notification, risk behaviour change was similar for both sexes, with the pattern of change being similar in both arms. Between screening and the PTN-RA, significant reductions in number of sexual partners (p \< 0.001), and unprotected sex (p \< 0.001). were observed. 677 participants completed the unblinding risk perception questionnaire. In this assessment, men were more likely to report behaviour change (22.0%) than women (14.1%). Men reported increased condom use (64.6%), encouraging partner testing (51.2%) and reduced partner numbers (57.3%). More vaccinees (24.7%) as compared to placebo recipients (12.1%) agreed/strongly agreed that they were more likely to get HIV than most people (p \< 0.001), which was attributed by the participant to receiving the vaccine.

Conclusion
==========

Post-unblinding, vaccinees perceived being at increased risk of HIV, but risk behaviour reductions were noted irrespective of treatment allocation.
